Compass Pathways (CMPS): What Will Come Out of FDA Review Meeting for Depression Drug Candidate COMP360?

Compass Pathways PLC (NASDAQ:CMPS) is among the best psychedelic stocks to buy in 2026. Its flagship psychedelic drug candidate COMP360 is aimed at treating patients with depression. COMP360 uses a type of psychedelic substance called psilocybin, and it’s in the final stages of studies. Compass Pathways PLC (CMPS): What Will Come Out of FDA Review Meeting for Depression Drug Candidate COMP360? Pressmaster/Shutterstock.com On March 3, Compass Pathways PLC (NASDAQ:CMPS) representatives attended TD Cowen’s ...